Complementary but Distinct Roles for MRI and 18F-Fluoromisonidazole PET in the Assessment of Human Glioblastomas

Glioblastoma multiforme is a primary brain tumor known for its rapid proliferation, diffuse invasion, and prominent neovasculature and necrosis. This study explores the in vivo link between these characteristics and hypoxia by comparing the relative spatial geometry of developing vasculature inferred from gadolinium-enhanced T1-weighted MRI (T1Gd), edematous tumor extent revealed on T2-weighted MRI (T2), and hypoxia assessed by 18F-fluoromisonidazole PET (18F-FMISO). Given the role of hypoxia in upregulating angiogenic factors, we hypothesized that the distribution of hypoxia seen on 18F-FMISO is correlated spatially and quantitatively with the amount of leaky neovasculature seen on T1Gd. Methods: A total of 24 patients with glioblastoma underwent T1Gd, T2, and 18F-FMISO—11 studies preceded surgical resection or biopsy, 7 followed surgery and preceded radiation therapy, and 11 followed radiation therapy. Abnormal regions seen on the MRI scan were segmented, including the necrotic center (T0), the region of abnormal blood–brain barrier associated with disrupted vasculature (T1Gd), and infiltrating tumor cells and edema (T2). The 18F-FMISO images were scaled to the blood 18F-FMISO activity to create tumor-to-blood ratio (T/B) images. The hypoxic volume (HV) was defined as the region with T/Bs greater than 1.2, and the maximum T/B (T/Bmax) was determined by the voxel with the greatest T/B value. Results: The HV generally occupied a region straddling the outer edge of the T1Gd abnormality and into the T2. A significant correlation between HV and the volume of the T1Gd abnormality that relied on the existence of a large outlier was observed. However, there was consistent correlation between surface areas of all MRI-defined regions and the surface area of the HV. The T/Bmax, typically located within the T1Gd region, was independent of the MRI-defined tumor size. Univariate survival analysis found the most significant predictors of survival to be HV, surface area of HV, surface area of T1Gd, and T/Bmax. Conclusion: Hypoxia may drive the peripheral growth of glioblastomas. This conclusion supports the spatial link between the volumes and surface areas of the hypoxic and MRI regions; the magnitude of hypoxia, T/Bmax, remains independent of size.

[1]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  J. Hendry,et al.  Radiobiology for the Radiologist , 1979, British Journal of Cancer.

[3]  K. Swanson,et al.  A mathematical model for glioma growth and invasion links biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET , 2007 .

[4]  Jean Charles Gilbert,et al.  Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  P. J. Green,et al.  Probability and Statistical Inference , 1978 .

[6]  M. Berridge,et al.  An efficient radiosynthesis of [18F]fluoromisonidazole. , 1993, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[7]  J. Murray,et al.  Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy , 2002, British Journal of Cancer.

[8]  F. O’Sullivan,et al.  Hypoxia and Glucose Metabolism in Malignant Tumors , 2004, Clinical Cancer Research.

[9]  D. Zagzag,et al.  Angiogenesis in Gliomas: Biology and Molecular Pathophysiology , 2005, Brain pathology.

[10]  Robert C. Rostomily,et al.  The cause of death in patients with glioblastoma is multifactorial: , 1991, Journal of Neuro-Oncology.

[11]  D. Mankoff,et al.  Hypoxia imaging-directed radiation treatment planning , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Thomas K. Lewellen,et al.  Investigation of the performance of the General Electric Advance positron emission tomograph in 3D mode , 1995 .

[13]  T. Chenevert,et al.  The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. , 2006, Cancer research.

[14]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[15]  J. Rasey,et al.  Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. , 1990, Radiation research.

[16]  S. Stylli,et al.  Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). , 2002, Nuclear medicine and biology.

[17]  F. O’Sullivan,et al.  Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival , 2008, Clinical Cancer Research.

[18]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[19]  David L. Schwartz,et al.  Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer , 2006, Clinical Cancer Research.

[20]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  N. van Bruggen,et al.  Assessing tumor angiogenesis using macromolecular MR imaging contrast media , 1997, Journal of magnetic resonance imaging : JMRI.

[22]  M. Slomiany,et al.  Hypoxia-Inducible Factor-1-Dependent and -Independent Regulation of Insulin-Like Growth Factor-1-Stimulated Vascular Endothelial Growth Factor Secretion , 2006, Journal of Pharmacology and Experimental Therapeutics.

[23]  P. Black,et al.  Growth Factors in Glioma Angiogenesis: FGFs, PDGF, EGF, and TGFs , 2000, Journal of Neuro-Oncology.